Fcγ1 fragment of IgG1 as a powerful affinity tag in recombinant Fc-fusion proteins: immunological, biochemical and therapeutic properties

References

• Waugh DS. Making the most of affinity tags. Trends Biotechnol. 2005;23:316–320.
   PubMed Web of Science ®Google Scholar
• Carter PJ. Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res. 2011;317:1261–1269.
   PubMed Web of Science ®Google Scholar
• Czajkowsky DM, Hu J, Shao Z, et al. Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med. 2012;4:1015–1028.
   PubMed Web of Science ®Google Scholar
• Levin D, Golding B, Strome SE, et al. Fc fusion as a platform technology: potential for immunogenicity. Trends Biotechnol. 2015;33:27–34.
   PubMed Web of Science ®Google Scholar
• Malhotra A. Tagging for protein expression. In: Richard RB, Murray PD, editors. Methods in enzymology. New York: Academic Press; 2009.
   Google Scholar
• Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 2012;119:3031–3037.
   PubMed Web of Science ®Google Scholar
• Lichty JJ, Malecki JL, Agnew HD, et al. Comparison of affinity tags for protein purification. Protein Expr Purif. 2005;41:98–105.
   PubMed Web of Science ®Google Scholar
• Terpe K. Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol. 2003;60:523–533.
   PubMed Web of Science ®Google Scholar
• Costa S, Almeida A, Castro A, et al. Fusion tags for protein solubility, purification and immunogenicity in Escherichia coli: the novel Fh8 system. Front Microbiol. 2014;63:1–20.
   Google Scholar
• Harper S, Speicher DW. Purification of proteins fused to glutathione S-transferase. Methods Mol Biol. 2011;681:259–280.
   PubMedGoogle Scholar
• GE Healthcare. 2009. Recombinant protein purification handbook: principles and methods. Chicago (IL): GE Healthcare Bio-Sciences.
   Google Scholar
• Arnau J, Lauritzen C, Petersen GE, et al. Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins. Protein Expr Purif. 2006;48:1–13.
   PubMed Web of Science ®Google Scholar
• Goldenberg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther. 1999;21:75–87.
   PubMed Web of Science ®Google Scholar
• Zhao X, Li G, Liang S. Several affinity tags commonly used in chromatographic purification. J Anal Methods Chem. 2013;2013:581093.
   PubMed Web of Science ®Google Scholar
• Smyth DR, Mrozkiewicz MK, McGrath WJ, et al. Crystal structures of fusion proteins with large-affinity tags. Protein Sci. 2003;12:1313–1322.
   PubMed Web of Science ®Google Scholar
• Capon DJ, Chamow SM, Mordenti J, et al. Designing CD4 immunoadhesins for AIDS therapy. Nature. 1989;337:525–531.
   PubMed Web of Science ®Google Scholar
• Zhang L, Ma W, Da J. [Mycobacterium vaccae influences the kinetics of Th1/Th2 cells and expression of iNOS in a marine model of experimental tuberculosis]. Zhonghua Jie He He Hu Xi Za Zhi. 2000;23:43–46.
   PubMedGoogle Scholar
• Ulrich H, Weidle BS, Georges G, et al. Genetically engineered fusion proteins for treatment of cancer. Cancer Genomics Proteomics. 2012;9:357–372.
   PubMed Web of Science ®Google Scholar
• Flynn JL, Triebold GM, Koller KJ, et al. Major histocompatibility complex class I restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA. 1992;89:12013–12017.
   PubMed Web of Science ®Google Scholar
• Gillies SD, Young D, Lo KM, et al. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjug Chem. 1993;4:230–235.
   PubMed Web of Science ®Google Scholar
• Terai M, Tamura Y, Alexeev V, et al. Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential. Cancer Immunol Immunother. 2009;58:1307–1317.
   PubMed Web of Science ®Google Scholar
• Soleimanpour S, Farsiani H, Mosavat A, et al. APC targeting enhances immunogenicity of a novel multistage Fc-fusion tuberculosis vaccine in mice. Appl Microbiol Biotechnol. 2015;99:10467–10480.
   PubMed Web of Science ®Google Scholar
• Rezaee SA, Gracie JA, Mcinnes IB, et al. Inhibition of neutrophil function by the Kaposi's sarcoma-associated herpesvirus Vox2 protein. AIDS. 2005;19:1907–1910.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371:395–403.
   PubMed Web of Science ®Google Scholar
• Friden PM, Walus LR, Watson P, et al. Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science. 1993;259:373–377.
   PubMed Web of Science ®Google Scholar
• Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther. 2007;7:1401–1413.
   PubMed Web of Science ®Google Scholar
• Natsume A, In M, Takamura H, et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res. 2008;68:3863–3872.
   PubMed Web of Science ®Google Scholar
• Grevys A, Bern M, Foss S, et al. Fc engineering of human IgG1 for altered binding to the neonatal Fc receptor affects Fc effector functions. J Immunol. 2015;194:5497–5508.
   PubMed Web of Science ®Google Scholar
• Lux A, Yu X, Scanlan CN, et al. Impact of immune complex size and glycosylation on IgG binding to human FcγRs. J Immunol. 2013;190:4315–4323.
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 2009;8:226–234.
   PubMed Web of Science ®Google Scholar
• Korhonen R, Moilanen E. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol. 2009;104:276–284.
   PubMed Web of Science ®Google Scholar
• Strober BE, Menon K. Alefacept for the treatment of psoriasis and other dermatologic diseases. Dermatol Ther. 2007;20:270–276.
   PubMed Web of Science ®Google Scholar
• Cines DB, Yasothan U, Kirkpatrick P. Romiplostim. Nat Rev Drug Discov. 2008;7:887–888.
   PubMed Web of Science ®Google Scholar
• van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003;124:1774–1785.
   PubMed Web of Science ®Google Scholar
• Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002;301:418–426.
   PubMed Web of Science ®Google Scholar
• Hamilton K, Clair EW. Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis. Expert Opin Pharmacother. 2000;1:1041–1052.
   PubMedGoogle Scholar
• Peters RT, Low SC, Kamphaus GD, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood. 2010;115:2057–2064.
   PubMed Web of Science ®Google Scholar
• Jonsson G, Oxelius VA, Truedsson L, et al. Homozygosity for the IgG2 subclass allotype G2M(n) protects against severe infection in hereditary C2 deficiency. J Immunol. 2006;177:722–728.
   PubMed Web of Science ®Google Scholar
• Sarvas H, Rautonen N, Kayhty H, et al. Effect of Gm allotypes on IgG2 antibody responses and IgG2 concentrations in children and adults. Int Immunol. 1990;2:317–322.
   PubMed Web of Science ®Google Scholar
• Saltz L, Easley C, Kirkpatrick P. Panitumumab. Nat Rev Drug Discov. 2006;5:987–988.
   PubMed Web of Science ®Google Scholar
• Helguera G, Rodriguez JA, Penichet ML. Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors. Mol Cancer Ther. 2006;5:1029–1040.
   PubMed Web of Science ®Google Scholar
• Penichet ML, Dela Cruz JS, Shin SU, et al. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Hum Antibodies. 2001;10:43–49.
   PubMedGoogle Scholar
• Aalberse RC, Schuurman J. IgG4 breaking the rules. Immunology. 2002;105:9–19.
   PubMed Web of Science ®Google Scholar
• Amico D, Barbui AM, Erba E, et al. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood. 2003;101:4589–4597.
   PubMed Web of Science ®Google Scholar
• Rosales C. UQE, Fc receptors: cell activators of antibody functions. Adv Biosci Biotechnol. 2013;4:21–33.
   Google Scholar
• Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood. 2012;119:5640–5649.
   PubMed Web of Science ®Google Scholar
• Amigorena S, Choquet BC, Fridman D, et al. Fc gamma RII expression in resting and activated B lymphocytes. Eur JImmunol. 1989;19:1379–1385.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34–47.
   PubMed Web of Science ®Google Scholar
• Ansel M, Lee DU, Rao A. An epigenetic view of helper T cell differentiation. Nat Immunol. 2003;4:616–623.
   PubMed Web of Science ®Google Scholar
• Wilson CB, Rowell E, Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol. 2009;9:91–105.
   PubMed Web of Science ®Google Scholar
• Guo Y, Kang W, Zhong Y, et al. Purification and characterization of human IL-10/Fc fusion protein expressed in Pichia pastoris. Protein Expr Purif. 2012;83:152–156.
   PubMed Web of Science ®Google Scholar
• Konduru K, Shurtleff A, Bavari S, et al. Evaluation of ebolavirus glycoprotein Fc fusion protein as a subunit vaccine (P4417). J Immunol. 2013;190:205–218.
   PubMed Web of Science ®Google Scholar
• Loureiro S, Ren J, Phapugrangkul P, et al. Adjuvant-free immunization with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines. J Virol. 2010;85:3010–3014.
   PubMed Web of Science ®Google Scholar
• Silva MT. Neutrophils and macrophages work in concert as inducers and effectors of adaptive immunity against extracellular and intracellular microbial pathogens. J Leukoc Biol. 2010;87:805–813.
   PubMed Web of Science ®Google Scholar
• Rossi M, Young JW. Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J Immunol. 2005;175:1373–1381.
   PubMed Web of Science ®Google Scholar
• Hildner K, Edelson BT, Purtha WE, et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science. 2008;322:1097–1100.
   PubMed Web of Science ®Google Scholar
• Jongbloed SL, Kassianos AJ, McDonald KJ, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med. 2010;207:1247–1260.
   PubMed Web of Science ®Google Scholar
• Baker K, Qiao SW, Kuo TT, et al. Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells. Proc Natl Acad Sci USA. 2011;108:9927–9932.
   PubMed Web of Science ®Google Scholar
• David NA, Mekhaiel DM, Andersen JT, et al. Polymeric human Fc-fusion proteins with modified effector functions. Sci Rep. 2011;1:124–135.
   PubMed Web of Science ®Google Scholar
• Kaplan G. Filovirus vaccines. J Vaccines Vaccin. 2012;7:701–711.
   Google Scholar
• Konduru K, Bradfute SB, Jacques J, et al. Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice. Vaccine. 2011;29:2968–2977.
   PubMed Web of Science ®Google Scholar
• Rath T, Baker K, Dumont JA, et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol. 2015;35:235–254.
   PubMed Web of Science ®Google Scholar
• Chames P, van Regenmortel M, Weiss E, et al. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157:220–233.
   PubMed Web of Science ®Google Scholar
• Lo KM, Sudo Y, Chen J, et al. High level expression and secretion of Fc-X fusion proteins in mammalian cells. Protein Eng. 1998;11:495–500.
   PubMedGoogle Scholar
• Thompson JD, Gibson TJ, Plewniak F, et al. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 1997;25:4876–4882.
   PubMed Web of Science ®Google Scholar
• Misstear K, Chanas SA, Rezaee SA, et al. Suppression of antigen-specific T cell responses by the Kaposi's sarcoma-associated herpesvirus viral OX2 protein and its cellular orthologue, CD200. J Virol. 2012;86:6246–6257.
   PubMed Web of Science ®Google Scholar
• Spiller OB, Robinson M, O'Donnell E, et al. Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein. J Virol. 2003;77:592–599.
   PubMed Web of Science ®Google Scholar
• Villaverde A, Carrio MM. Protein aggregation in recombinant bacteria: biological role of inclusion bodies. Biotechnol Lett. 2003;25:1385–1395.
   PubMed Web of Science ®Google Scholar
• Chennamsetty N, Voynov V, Kayser V, et al. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci USA. 2009;106:11937–11942.
   PubMed Web of Science ®Google Scholar
• Chamow SM, Ryll T, Henry B, et al. 2014. Therapeutic Fc fusion proteins. Hoboken (NJ): Wiley-Blackwell.
   Google Scholar
• Kontermann R. Therapeutic proteins: strategies to modulate their plasma half-lives. Weinheim: Wiley-Blackwell; 2012.
   Google Scholar
• Strauch EM, Fleishman SJ, Baker D. Computational design of a pH-sensitive IgG binding protein. Proc Natl Acad Sci USA. 2014;111:675–680.
   PubMed Web of Science ®Google Scholar
• Amersham Pharmacia Biotech. The recombinant protein handbook: protein amplification and simple purification. Uppsala, Sweden: Amersham Pharmacia Biotech; 2009.
   Google Scholar
• Dalton AC, Barton WA. Over-expression of secreted proteins from mammalian cell lines. Protein Sci. 2014;23:517–525.
   PubMed Web of Science ®Google Scholar
• Grillberger L, Kreil TR, Nasr S, et al. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J. 2009;4:186–201.
   PubMedGoogle Scholar
• Amini AA, Solovyova AS, Sadeghian H, et al. Structural properties of a viral orthologue of cellular CD200 protein: KSHV vOX2. Virology. 2015;474:94–104.
   PubMed Web of Science ®Google Scholar
• Meisterernst M, Roeder RG. Family of proteins that interact with TFIID and regulate promoter activity. Cell. 1991;67:557.
   PubMed Web of Science ®Google Scholar
• Yang T, Wang Z, Wu F, et al. A variant of TNFR2-Fc fusion protein exhibits improved efficacy in treating experimental rheumatoid arthritis. PLoS Comput Biol. 2010;6:e1000669.
   PubMed Web of Science ®Google Scholar
• Cannon JP, O'Driscoll M, Litman GW. Construction, expression, and purification of chimeric protein reagents based on immunoglobulin fc regions. Methods Mol Biol. 2011;748:51–67.
   PubMedGoogle Scholar
• Gerstner JA, Bell JA, Cramer SM. Gibbs free energy of adsorption for biomolecules in ion-exchange systems. Biophys Chem. 1994;52:97–106.
   PubMed Web of Science ®Google Scholar
• Amersham Pharmacia Biotech. Affinity chromatography: principles and methods. Uppsala, Sweden: Amersham Pharmacia Biotech AB; 2007.
   Google Scholar
• Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol. 2011;22:868–876.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ishii-Watabe A, Tada M, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol. 2010;184:1968–1976.
   PubMed Web of Science ®Google Scholar
• Weimer T, Metzner HJ, Schulte S. Recombinant albumin fusion proteins. In: Schmidt SR, editor. Fusion protein technologies for biopharmaceuticals: applications and challenges. Laupheim, Germany: John Wiley and Sons; 2013.
   Google Scholar
• Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci. 2008;97:4167–4183.
   PubMed Web of Science ®Google Scholar
• Linderholm AL, Chamow SM. Immunoglobulin Fc-fusion proteins. Part 1: their design and manufacture. BioProcess Int. 2014b;12:30–35.
   Google Scholar
• Kandil E, Egashira M, Miyoshi O, et al. The human gene encoding the heavy chain of the major histocompatibility complex class I-like Fc receptor (FCGRT) maps to 19q13.3. Cytogenet Cell Genet. 1996;73:97–98.
   PubMedGoogle Scholar
• Petkova SB, Akilesh S, Sproule TJ, et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol. 2006;18:1759–1769.
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715–725.
   PubMed Web of Science ®Google Scholar
• Ghetie V, Hubbard JG, Kim J, et al. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol. 1996;26:690–696.
   PubMed Web of Science ®Google Scholar
• Israel EJ, Wilsker DF, Hayes KC, et al. Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology. 1996;89:573–578.
   PubMed Web of Science ®Google Scholar
• Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. MAbs. 2011;3:422–430.
   PubMed Web of Science ®Google Scholar
• Presta LG. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol. 2008;20:460–470.
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Capon DJ, Ward RHR. Immunoadhesins. Int Rev Immunol. 1993;10:219–227.
   PubMedGoogle Scholar
• Lu L, Palaniyandi S, Zeng R, et al. A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection. J Virol. 2011;85:10542–10553.
   PubMed Web of Science ®Google Scholar
• Pepponi I, Stylianou DG, van Dolleweerd E, et al. Plant-derived recombinant immune complexes as self-adjuvanting TB immunogens for mucosal boosting of BCG. Plant Biotechnol J. 2014;12:840–850.
   PubMed Web of Science ®Google Scholar
• Achuthanandam R, Makropoulos D, Johns L, Volk A, et al. Pharmacodynamics of CNTO 530 and darbepoetin-α in human TNF-α transgenic mice, a murine model of anemia of chronic disease. Pharmacol Pharm. 2011;2:17–30.
   Google Scholar
• Hartmann N, Messmann JJ, Leithauser F, et al. Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions. Blood. 2013;121:556–565.
   PubMed Web of Science ®Google Scholar
• Jimenez-Solem E, Rasmussen MH, Christensen M, et al. Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. Curr Opin Mol Ther. 2010;12:790–797.
   PubMed Web of Science ®Google Scholar
• Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov. 2012;11:311–331.
   PubMed Web of Science ®Google Scholar
• Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013;13:176–189.
   PubMed Web of Science ®Google Scholar
• Liang S, Dai J, Hou S, et al. Structural basis for treating tumor necrosis factor alpha (TNFalpha)-associated diseases with the therapeutic antibody infliximab. J Biol Chem. 2013;288:13799–13807.
   PubMed Web of Science ®Google Scholar
• Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131:308–316.
   PubMed Web of Science ®Google Scholar
• Moreland L, Bate G, Kirkpatrick P. Abatacept. Nat Rev Drug Discov. 2006;5:185–186.
   PubMed Web of Science ®Google Scholar
• Strome SE, Sausville EA, Mann D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist. 2007;12:1084–1095.
   PubMed Web of Science ®Google Scholar
• Fotino C, Ricordi C, Lauriola V, et al. Bone marrow-derived stem cell transplantation for the treatment of insulin-dependent diabetes. Rev Diabet Stud. 2010;7:144–157.
   PubMedGoogle Scholar
• Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267–296.
   PubMed Web of Science ®Google Scholar
• Waldmann TA. A novel means of favorably tipping the balance between cytopathic and regulatory T cells. Immunity. 2003;19:465–466.
   PubMed Web of Science ®Google Scholar
• Nomura T, Sakaguchi S. Naturally arising CD25+CD4+ regulatory T cells in tumor immunity. Curr Top Microbiol Immunol. 2005;293:287–302.
   PubMed Web of Science ®Google Scholar
• Linderholm A, Chamow SM. Immunoglobulin Fc-fusion proteins part 2: therapeutic uses and clinical development. BioProcess Int. 2014a;12:2–7.
   Google Scholar
• Scheinfeld N. Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for psoriasis. J Dermatol Treat. 2007;18:197–208.
   PubMed Web of Science ®Google Scholar
• Emamaullee J, Toso C, Merani S, et al. Costimulatory blockade with belatacept in clinical and experimental transplantation – a review. Expert Opin Biol Ther. 2009;9:789–796.
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Throne ML, Amar NJ, et al. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther. 2012;34:2091–2103.
   PubMed Web of Science ®Google Scholar
• Holash J, Papadopoulos DS, Croll N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99:11393–11398.
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039–2049.
   PubMed Web of Science ®Google Scholar
• Gater A, Thomson TA, Strandberg-Larsen M. Haemophilia B: impact on patients and economic burden of disease. Thromb Haemost. 2011;106:398–404.
   PubMed Web of Science ®Google Scholar
• Gillies SD, Lan Y, Brunkhorst B, et al. Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer. Cancer Immunol Immunother. 2002;51:449–460.
   PubMed Web of Science ®Google Scholar
• Dumont JA, Bitonti AJ, Clark D, et al. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J Aerosol Med. 2005;18:294–303.
   PubMedGoogle Scholar
• Low SC, Nunes SL, Bitonti AJ, et al. Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum Reprod. 2005;20:1805–1813.
   PubMed Web of Science ®Google Scholar
• Ko SY, Rudicell PA, Yang RS, et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature. 2014;514:642–645.
   PubMed Web of Science ®Google Scholar
• Weidle UH, Schneider B, Georges G, et al. Genetically engineered fusion proteins for treatment of cancer. Cancer Genomics Proteomics. 2012;9:357–372.
   PubMed Web of Science ®Google Scholar
• Greulich H, Pollock PM. Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med. 2011;17:283–292.
   PubMed Web of Science ®Google Scholar
• Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116–129.
   PubMed Web of Science ®Google Scholar
• Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J. 2011;437:199–213.
   PubMed Web of Science ®Google Scholar
• Harding TC, Long L, Palencia S, et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci Transl Med. 2013;5:178ra39.
   PubMed Web of Science ®Google Scholar
• Bianchi R, Fischer E, Yuen D, et al. Mutation of threonine 34 in mouse podoplanin-Fc reduces CLEC-2 binding and toxicity in vivo while retaining antilymphangiogenic activity. J Biol Chem. 2014;289:21016–21027.
   PubMed Web of Science ®Google Scholar
• Cueni LN, Chen L, Zhang H, et al. Podoplanin-Fc reduces lymphatic vessel formation in vitro and in vivo and causes disseminated intravascular coagulation when transgenically expressed in the skin. Blood. 2010;116:4376–4384.
   PubMed Web of Science ®Google Scholar
• Gale NW, Thurston G, Hackett SF, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell. 2002;3:411–423.
   PubMed Web of Science ®Google Scholar
• Huang H, Bhat A, Woodnutt G, et al. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer. 2010;10:575–585.
   PubMed Web of Science ®Google Scholar
• Neal J, Wakelee H. AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. Curr Opin Mol Ther. 2010;12:487–495.
   PubMedGoogle Scholar
• Dieras V, Wildiers H, Jassem J, et al. Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: a phase 2 randomized study. Breast. 2015;24:182–190.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Hong D, Chap L, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol. 2009;27:3557–3565.
   PubMed Web of Science ®Google Scholar
• Robson EJ, Ghatage P. AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer. Expert Opin Investig Drugs. 2011;20:297–304.
   PubMed Web of Science ®Google Scholar
• Gorczynski RM, Chen Z, Yu K, et al. CD200 immunoadhesin suppresses collagen-induced arthritis in mice. Clin Immunol. 2001;101:328–334.
   PubMed Web of Science ®Google Scholar
• Zhang S, Cherwinski H, Sedgwick JD, et al. Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol. 2004;173:6786–6793.
   PubMed Web of Science ®Google Scholar
• Rezaee SA, Cunningham C, Davison AJ, et al. Kaposi's sarcoma-associated herpesvirus immune modulation: an overview. J Gen Virol. 2006;87:1781–1804.
   PubMed Web of Science ®Google Scholar
• Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278:3466–3473.
   PubMed Web of Science ®Google Scholar
• Stavenhagen JB, Gorlatov S, Tuaillon N, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors. Cancer Res. 2007;67:8882–8890.
   PubMed Web of Science ®Google Scholar
• Harris CL, Lublin DM, Morgan BP. Efficient generation of monoclonal antibodies for specific protein domains using recombinant immunoglobulin fusion proteins: pitfalls and solutions. J Immunol Methods. 2002;268:245–258.
   PubMed Web of Science ®Google Scholar
• Lighvani AA, Frucht DM, Jankovic D, et al. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Natl Acad Sci USA. 2001;98:15137–15142.
   PubMed Web of Science ®Google Scholar
• Mullen AC, High FA, Hutchins AS, et al. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science. 2001;292:1907–1910.
   PubMed Web of Science ®Google Scholar
• Loureiro S, Ren J, Phapugrangkul P, et al. Adjuvant-free immunization with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines. J Virol. 2011;85:3010–3014.
   PubMed Web of Science ®Google Scholar
• Shoji-Hosaka E, Kobayashi Y, Wakitani M, et al. Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides. J Biochem. 2006;140:777–783.
   PubMed Web of Science ®Google Scholar
• Byrn RA, Mordenti J, Lucas C, et al. Biological properties of a CD4 immunoadhesin. Nature. 1990;344:667–670.
   PubMed Web of Science ®Google Scholar
• Martinez-Pomares L. Exploiting Fc chimaeric proteins for the identification of ligands specific for the mannose receptor. Methods Mol Biol. 2009;531:103–122.
   PubMedGoogle Scholar
• Strbo N, Garcia-Soto A, Schreiber TH, et al. Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases. Immunol Res. 2013;57:311–325.
   PubMed Web of Science ®Google Scholar
• Koh YJ, Kim HZ, Hwang SI, et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell. 2010;18:171–184.
   PubMed Web of Science ®Google Scholar
• Sarup J, Jin P, Turin L, et al. Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts. Mol Cancer Ther. 2008;7:3223–3236.
   PubMed Web of Science ®Google Scholar
• Smolewski P, Robak P, Cebula-Obrzut B, et al. Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies. Eur J Cancer. 2014;50:2677–2684.
   PubMed Web of Science ®Google Scholar
• Raran-Kurussi S, Waugh DS. The ability to enhance the solubility of its fusion partners is an intrinsic property of maltose-binding protein but their folding is either spontaneous or chaperone-mediated. PLoS One. 2012;7:e49589.
   PubMed Web of Science ®Google Scholar
• Nallamsetty S, Waugh DS. Solubility-enhancing proteins MBP and NusA play a passive role in the folding of their fusion partners. Protein Expr Purif. 2006;45:175–182.
   PubMed Web of Science ®Google Scholar